Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Simon Lord"'
Autor:
Sarah P. Blagden, Francesca M. Buffa, Isaac Kitchen-Smith, Natasha Sahgal, Matteo Di Giovannantonio, Adrian L. Harris, Gareth L. Bond, Simon Lord, Giovanni Stracquadanio, Lingyun Xiong, David A. Harris, Marsha D. Wallace, Benjamin Howell Lole Harris, Ping Zhang
Publikováno v:
Journal of Medical Genetics
Di Giovannantonio, M, Harris, B H, Zhang, P, Kitchen-Smith, I, Xiong, L, Sahgal, N, Stracquadanio, G, Wallace, M, Blagden, S, Lord, S, Harris, D, Harris, A H L, Buffa, F M & Bond, G L 2020, ' Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits ', Journal of Medical Genetics . https://doi.org/10.1136/jmedgenet-2019-106799
Di Giovannantonio, M, Harris, B H, Zhang, P, Kitchen-Smith, I, Xiong, L, Sahgal, N, Stracquadanio, G, Wallace, M, Blagden, S, Lord, S, Harris, D, Harris, A H L, Buffa, F M & Bond, G L 2020, ' Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits ', Journal of Medical Genetics . https://doi.org/10.1136/jmedgenet-2019-106799
BackgroundHeight and other anthropometric measures are consistently found to associate with differential cancer risk. However, both genetic and mechanistic insights into these epidemiological associations are notably lacking. Conversely, inherited ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcb984c6d2a9691912d426cf78cb43cf
https://hdl.handle.net/11565/4052495
https://hdl.handle.net/11565/4052495
Autor:
Analia Azaro, Jordi Rodon, Constanza Linossi, Richard D. Baird, Ulrike Fiedler, Simon Lord, Keith M. Dawson, Aurelius Omlin, Nicolas Leupin, Andreas Harstrick, Stefanie Fischer, Michael T. Stumpp, Christof Zitt, Mark R. Middleton, Adrian L. Harris
Publikováno v:
Journal of Clinical Oncology
PURPOSE A first-in-human study was performed with MP0250, a DARPin drug candidate. MP0250 specifically inhibits both vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) with the aim of disrupting the tumor microenvironment. P
Autor:
John Pollard, Robert Wesolowski, Bart S. Hendriks, Craig Devoe, Martin H. Falk, Timothy A. Yap, Geoffrey I. Shapiro, Simon Lord, Ivan Diaz-Padilla, Ruth Plummer
Publikováno v:
British Journal of Cancer
BackgroundBerzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We assessed the safety, tolerability, pharmacokinetics, and preliminary eff
Autor:
Mark R. Middleton, P S Virdee, Leena Elhussein, Martin Eatock, M Goff, Sharon Love, Anne Thomas, Stephen Falk, Joanna Moschandreas, Richard C. Turkington, D. Alan Anthoney, L Collins, Simon Lord
Publikováno v:
Thomas, A, Virdee, P S, Eatock, M, Lord, S R, Falk, S, Anthoney, D A, Turkington, R C, Goff, M, Elhussein, L, Collins, L, Love, S, Moschandreas, J & Middleton, M R 2020, ' Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma ', European Journal of Cancer, vol. 124, pp. 131-141 . https://doi.org/10.1016/j.ejca.2019.10.010
European Journal of Cancer
European Journal of Cancer
Background AZD8931 has equipotent activity against epidermal growth factor receptor, erbB2, and erbB3. Primary objectives were to determine the recommended phase II dose (RP2D) of AZD8931 + chemotherapy, and subsequently assess safety/preliminary cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3f3f4d7b04b1b1073ec0ebfa84b2946
https://pure.qub.ac.uk/en/publications/1ea96e9e-4701-4ab7-aa91-f416c1e2f897
https://pure.qub.ac.uk/en/publications/1ea96e9e-4701-4ab7-aa91-f416c1e2f897
Autor:
Iain R. Macpherson, Ferry A.L.M. Eskens, Norbert P Koper, Elisabeth G.E. de Vries, Christian Rolfo, Cristina Saura, Sylvie Rottey, Udai Banerji, Jill J.J. Geenen, Marta Gil-Martin, Philippe Aftimos, Victor Moreno, E.C. Mommers, Simon Lord, Valentina Boni, Carla M.L. van Herpen, Fiona C Thistlethwaite
Publikováno v:
Lancet Oncology, 20(8), 1124-1135. ELSEVIER SCIENCE INC
The lancet oncology
Lancet Oncology, 20(8), 1124-1135. Lancet Publishing Group
Dipòsit Digital de la UB
Universidad de Barcelona
Lancet Oncology, 20, 1124-1135
Lancet Oncology, 20, 8, pp. 1124-1135
The lancet oncology
Lancet Oncology, 20(8), 1124-1135. Lancet Publishing Group
Dipòsit Digital de la UB
Universidad de Barcelona
Lancet Oncology, 20, 1124-1135
Lancet Oncology, 20, 8, pp. 1124-1135
Background Trastuzumab duocarmazine is a novel HER2-targeting antibody-drug conjugate comprised of trastuzumab covalently bound to a linker drug containing duocarmycin. Preclinical studies showed promising antitumour activity in various models. In th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b70692fb1a9fc695d8ac5957d5b08452
https://eprints.gla.ac.uk/185727/7/185727.pdf
https://eprints.gla.ac.uk/185727/7/185727.pdf
Autor:
Maria Marples, Simon Lord, Patrick Hamilton, Peter Hall, Mehran Afshar, Dan Stark, Jenny F. Seligmann, Paul D. Baxter
Publikováno v:
Afshar, M, Hamilton, P, Seligmann, J, Lord, S, Baxter, P, Marples, M, Stark, D & Hall, P S 2015, ' Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)? ', Cancer investigation, pp. 1-7 . https://doi.org/10.3109/07357907.2015.1047504
Imatinib therapy has improved outcomes in advanced GISTs. Current guidelines suggest monitoring with CT scanning every 12 weeks. There are no validated biomarkers to assist disease evaluation. We identified 50 patients treated with imatinib for GIST
Publikováno v:
Clinical oncology (Royal College of Radiologists (Great Britain)). 22(2)
Most patients with advanced gastroesophageal cancer are elderly, but current standard regimens have emerged from trials predominantly involving patients with a median age65 years. The aim of this study was to assess the factors influencing survival o